Experimental combo aims to boost stem cell transplant success in rare blood cancers
NCT ID NCT02512497
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 38 times
Summary
This early-phase study tested adding the drug romidepsin to standard chemotherapy before and after a stem cell transplant in 23 adults with certain T-cell cancers (like lymphoma or leukemia). The main goals were to find the safest dose and see if the combination helps control the cancer long-term. Participants received the drugs before transplant and then romidepsin afterward to try to prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.